Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

NewsGuard 100/100 Score

Inhibitex, Inc. (Nasdaq: INHX) today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults. The SA3Ag vaccine contains an antigen originating from the Company’s MSCRAMM® protein platform. The Company licensed its MSCRAMM® protein platform to Wyeth (acquired by Pfizer in 2009) on an exclusive worldwide basis for the development of active vaccines against staphylococcus in 2001. Pfizer is responsible for all clinical development, manufacturing and marketing of the vaccine. Inhibitex is eligible to receive a payment upon the achievement of this and future regulatory milestones, as well as royalties on future net sales.

In addition to announcing the initiation of this Phase I vaccine study, the Company also provided an update on the status of FV-100, a highly potent oral antiviral compound in Phase II clinical development for the treatment of herpes zoster (shingles), and INX-189, a nucleotide polymerase inhibitor in late preclinical development for the treatment for chronic infections caused by hepatitis C virus (HCV).


Inhibitex, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New malaria vaccine strain shows promise in preclinical trials